Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Tianjin MasterVision Technology Co., Ltd.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Tianjin MasterVision Technology Co., Ltd.

Regulatory records
1
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 1 FDA record to the applicant name Tianjin MasterVision Technology Co., Ltd.. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 5, 2026 to Aug 5, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code NUU appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P220015, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: # 89 Heyuan Rd., Jing-Jin Technology Valley, 1st Floor # 15 Bldg., Tianjin, 301721. Recorded on P220015, decision dated Aug 5, 2026.

Changes described in PMA records

P220015: DilightTM (roflufocon E) Overnight Orthokeratology Contact Lens

FDA’s recorded scope: Approval for DilightTM (roflufocon E) Overnight Orthokeratology Contact Lens. The lenses are indicated for use in the reduction of myopic refractive error in non-diseased eyes. The lens is indicated for overnight wear for the temporary reduction of myopia up to 4.00 diopters (manifest spherical equivalent) in eyes with astigmatism up to 1.50 diopters. The lenses may only be disinfected using a chemical disinfection system. Note: To maintain the Orthokeratology effect overnight lens wear must be continued on a prescribed schedule. Failure to do so can affect daily activities (e.g., night driving), cause visual fluctuations, and changes in intended correction.

Aug 5, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Tianjin MasterVision Technology Co., Ltd.PMA approvalAug 5, 2026FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.